PL367204A1 - Zastosowanie L-karnityny jako czynnika stabilizującego białka - Google Patents

Zastosowanie L-karnityny jako czynnika stabilizującego białka

Info

Publication number
PL367204A1
PL367204A1 PL00367204A PL36720400A PL367204A1 PL 367204 A1 PL367204 A1 PL 367204A1 PL 00367204 A PL00367204 A PL 00367204A PL 36720400 A PL36720400 A PL 36720400A PL 367204 A1 PL367204 A1 PL 367204A1
Authority
PL
Poland
Prior art keywords
proteins
carnitine
stabilizing agent
chaperone
activity
Prior art date
Application number
PL00367204A
Other languages
English (en)
Other versions
PL199984B1 (pl
Inventor
Menotti Calvani
Original Assignee
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. filed Critical Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Priority to PL367204A priority Critical patent/PL199984B1/pl
Publication of PL367204A1 publication Critical patent/PL367204A1/pl
Publication of PL199984B1 publication Critical patent/PL199984B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
PL367204A 2000-12-15 2000-12-15 Zastosowanie L-karnityny jako czynnika stabilizującego białka PL199984B1 (pl)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL367204A PL199984B1 (pl) 2000-12-15 2000-12-15 Zastosowanie L-karnityny jako czynnika stabilizującego białka

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL367204A PL199984B1 (pl) 2000-12-15 2000-12-15 Zastosowanie L-karnityny jako czynnika stabilizującego białka
PCT/IT2000/000520 WO2002048190A1 (en) 2000-12-15 2000-12-15 Use of l-carnitine as stabilizing agent of proteins

Publications (2)

Publication Number Publication Date
PL367204A1 true PL367204A1 (pl) 2005-02-21
PL199984B1 PL199984B1 (pl) 2008-11-28

Family

ID=11133601

Family Applications (1)

Application Number Title Priority Date Filing Date
PL367204A PL199984B1 (pl) 2000-12-15 2000-12-15 Zastosowanie L-karnityny jako czynnika stabilizującego białka

Country Status (15)

Country Link
US (1) US7833977B2 (pl)
EP (1) EP1341813B1 (pl)
AT (1) ATE339445T1 (pl)
AU (1) AU2001223953A1 (pl)
CA (1) CA2434911C (pl)
CY (1) CY1106235T1 (pl)
DE (1) DE60030787T2 (pl)
DK (1) DK1341813T3 (pl)
ES (1) ES2272351T3 (pl)
HU (1) HU230002B1 (pl)
MX (1) MXPA03006266A (pl)
PL (1) PL199984B1 (pl)
PT (1) PT1341813E (pl)
SK (1) SK287787B6 (pl)
WO (1) WO2002048190A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6124201A (en) 2000-05-03 2001-11-12 Expressive Constructs Inc A method and device for improving protein stability and solubility
MXPA03006266A (es) 2000-12-15 2004-06-25 Sigma Tau Ind Farmaceuti Uso de l-carnitina como agente estabilizador de proteinas.
EP1624886A2 (en) * 2003-05-12 2006-02-15 Expressive Constructs, Inc. Methods for increasing cell and tissue viability
WO2011075430A1 (en) * 2009-12-14 2011-06-23 University Of Massachusetts Methods of inhibiting cataracts and presbyopia
US20200140500A1 (en) * 2012-07-17 2020-05-07 The Regents Of The University Of Michigan High throughput methods, protein inhibitors, and uses thereof
AU2014236582B2 (en) 2013-03-14 2018-03-29 The University Of Massachusetts Methods of inhibiting cataracts and presbyopia
CR20180294A (es) 2015-11-13 2018-08-10 Univ Massachusetts Moléculas bifuncionales que contienen peg para uso en la inhibición de cataratas y presbicia
CN119258202A (zh) * 2023-07-05 2025-01-07 重庆誉颜制药有限公司 一种肉毒毒素蛋白组合物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1235153B (it) * 1988-11-15 1992-06-22 Sigma Tau Ind Farmaceuti Uso dell'acetil l-carnitina nel trattamento terapeutico della cataratta e composizioni farmaceutiche utili in tale trattamento
US20040058015A1 (en) * 2000-06-01 2004-03-25 Yuanjin Tao Compositions and methods for treating eye discomfort and eye disease
MXPA03006266A (es) 2000-12-15 2004-06-25 Sigma Tau Ind Farmaceuti Uso de l-carnitina como agente estabilizador de proteinas.
ITRM20010294A1 (it) * 2001-05-29 2002-11-29 Sigma Tau Ind Farmaceuti Uso della acetil l-carnetina in associazione con la biotina per il trattamento di pazienti affetti da diabete mellito di tipo ii insulino re
US6923960B2 (en) * 2001-10-03 2005-08-02 Vsl Pharmaceuticals Inc. Antioxidant combination composition and use thereof
US20050163873A1 (en) * 2004-01-14 2005-07-28 Robert Ritch Methods and formulations for treating glaucoma
ITRM20040327A1 (it) * 2004-07-01 2004-10-01 Sigma Tau Ind Farmaceuti Uso della acetil l-carnitina per la preparazione di un medicamento per il trattamento del dolore neuropatico in pazienti diabetici.
US8569366B2 (en) * 2005-04-26 2013-10-29 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Acetyl L-carnitine for prevention of painful peripheral neuropathy in patients with type 2 diabetes

Also Published As

Publication number Publication date
DK1341813T3 (da) 2007-01-15
SK8902003A3 (en) 2003-12-02
DE60030787T2 (de) 2007-09-13
HUP0400737A3 (en) 2013-06-28
CA2434911C (en) 2009-12-08
ES2272351T3 (es) 2007-05-01
CA2434911A1 (en) 2002-06-20
HUP0400737A2 (hu) 2004-07-28
MXPA03006266A (es) 2004-06-25
CY1106235T1 (el) 2011-06-08
EP1341813B1 (en) 2006-09-13
EP1341813A1 (en) 2003-09-10
PT1341813E (pt) 2007-01-31
WO2002048190A1 (en) 2002-06-20
DE60030787D1 (de) 2006-10-26
PL199984B1 (pl) 2008-11-28
US20040120967A1 (en) 2004-06-24
US7833977B2 (en) 2010-11-16
SK287787B6 (sk) 2011-09-05
HU230002B1 (en) 2015-04-28
AU2001223953A1 (en) 2002-06-24
ATE339445T1 (de) 2006-10-15

Similar Documents

Publication Publication Date Title
ID24901A (id) Metode pengobatan keadaan terkoagulasi tinggi atau defisiensi protein c yang diperoleh
PL349335A1 (en) Method for the treatment of cerebral ischaemia and use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischaemia
AU2002341366A1 (en) Pharmaceutical preparations useful for treating tumors and lesions of the skin and the mucuous membranes
TW200605909A (en) Pharmaceutical preparation of recombinant factor VIII lyophilized without albumin as a stabilizer
NZ506408A (en) Pharmaceutical compositions
WO2003063780A3 (en) Therapeutic composition for treatment of cancer by arginine depletion
PL367204A1 (pl) Zastosowanie L-karnityny jako czynnika stabilizującego białka
ZA991749B (en) Pharmaceutical composition for prophylaxis and therapy of diseases associated with ocular fundus tissue cytopathy.
WO2007025142A3 (en) Gel compositions comprising a combination of an antiseptic and an anesthetic agent for treating surface areas in medical and surgical procedures
DK1343472T3 (da) Thixotropisk næsespray
IL163091A (en) Medical product and pharmaceutical composition comprising as active ingredients a thrombolytic agent and levosimendan or a pharmaceutically acceptable salt thereof and the use of same in the manufacture of medicament for reducing mortality of patients with acute myocardial infarction
DE60043886D1 (de) Formulierungen mit povidon-iod zur behandlung von wunden
BRPI0413481A (pt) cascas de lêvedos para o tratamento ou a prevenção da hiperglicemia ou para a estabilização da glicemia
RU2000101091A (ru) Способ лечения дистрофических заболеваний сетчатки и зрительного нерва
ES2182840T3 (es) Factor xiii para el tratamiento de heridas de la piel.
EP1361905B8 (en) Matrix protein compositions for guided connective tissue growth
DE69925312D1 (de) Bupropion zur behandlung von viralen erkrankungen
WO2001070951A3 (de) Mittel zur diagnose und therapie viraler erkrankungen
WO2001028578A3 (en) A PHARMACEUTICAL COMPOSITION CONTAINING pGLU-GLU-PRO-NH2 AND METHOD FOR TREATING DISEASES AND INJURIES TO THE BRAIN, SPINAL CORD AND RETINA USING SAME
RU94000695A (ru) Средство с противоаллергическим действием
DE602004025040D1 (de) Den blutzuckerspiegel bei diabetes mellitus regulierendes tetrapeptid
AU2003294834A1 (en) Anthranilic acid amide derivatives and their pharmaceutical use
WO2003097690A3 (en) Pth derivatives resistant to skin proteases
DE60040910D1 (de) Inaktivierte zytokine zur immunisierung
Berger Body composition changes with protease therapy